Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes

25 Jul 2017

Abstract excerpt

Hemoglobinopathies are inherited disorders of globin chains leading to decreased production of hemoglobin (Hb), the most significant being sickle cell disease (SCD) and β-thalassemia. Expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Bone and Joint Diseases
Share to Hemoglobinopathies and Related Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28738707
DOI: 10.1080/10428194.2017.1354373

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromesPMID 28738707Read ↗

Treatment with Azacitidine of Patients with End-Stage β-ThalassemiaSemantic proximity Read ↗

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.Semantic proximity Read ↗

Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemiaSemantic proximity Read ↗

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read ↗

Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemiaSemantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobinSemantic proximity Read ↗

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialSemantic proximity Read ↗

Therapy with azanucleosides for myelodysplastic syndromesSemantic proximity Read ↗

Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMMLSemantic proximity Read ↗

Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromesSemantic proximity Read ↗

Inactivation of HDAC 1 or HDAC 2 induces gamma globin expression without altering cell cycle or proliferationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.